About
Davion Healthcare Plc
Davion Healthcare Plc, a digital healthcare company, engages in the design, development, and commercialization of non-invasive health monitoring technologies.
Its core consumer health portfolio comprises proprietary, home-based monitoring devices designed to support the early identification of potential medical anomalies.
The company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature.
Davion Healthcare Plc Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Live Market Snapshot
Real-time price and trading activity
USD · NASDAQ:NASDAQ:DAVI
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-10-30 | $2.24 | $2.24 | $1.65 | $1.68 | $1.68 | -0.56 | 1,376,700 |
| 2026-10-29 | $3.13 | $3.20 | $2.59 | $2.69 | $2.69 | -0.44 | 4,176,100 |
| 2026-10-28 | $3.72 | $3.81 | $2.95 | $3.29 | $3.29 | -0.43 | 8,533,300 |
| 2026-10-27 | $3.72 | $3.99 | $2.78 | $3.00 | $3.00 | -0.72 | 6,069,900 |
| 2026-10-26 | $4.86 | $4.91 | $3.91 | $4.07 | $4.07 | -0.79 | 373,600 |
| 2026-10-23 | $8.89 | $8.89 | $5.67 | $6.00 | $6.00 | -2.89 | 479,500 |
| 2026-10-22 | $12.25 | $12.30 | $9.52 | $11.65 | $11.65 | -0.60 | 558,400 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 6-K | Oct 29, 2026 | Report of foreign issuer |
| 6-K | Oct 27, 2026 | Report of foreign issuer |
| CERT | Oct 21, 2026 | Certification by an exchange approving securities for listing |
| 424B3 | Oct 20, 2026 | Prospectus |
| 6-K | Oct 20, 2026 | Report of foreign issuer |
| 424B3 | Oct 13, 2026 | Prospectus |
| 6-K | Sep 15, 2026 | Report of foreign issuer |
| D | Sep 8, 2026 | Notice of Exempt Offering of Securities |
| POS AM | Sep 2, 2026 | Post-Effective amendments for registration statement |
| POS AM | Aug 17, 2026 | Post-Effective amendments for registration statement |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Glenn Williams
Chief Executive Officer
Andreas Ttofi
Chief Financial Officer
Jeremy North
Chief Operating Officer
